imatinib tad 100 mg film-coated tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - film-coated tablet - imatinib mesilate 100 mg - antineoplastic agents
imatinib tad 400 mg film-coated tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - film-coated tablet - imatinib mesilate 400 mg - antineoplastic agents
imatinib fresenius kabi 400 mg film-coat. tabl.
fresenius kabi deutschland gmbh - imatinib mesilate 478 mg - eq. imatinib 400 mg - film-coated tablet - 400 mg - imatinib mesilate 478 mg - imatinib
imatinib 100mg film-coated tablets
wockhardt uk limited - imatinib - film-coated tablet - 100 milligram(s) - other antineoplastic agents - protein-tyrosine kinase inhibitor - imatinib is indicated for the treatment of: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement.
imatinib 400mg film-coated tablets
wockhardt uk limited - imatinib - film-coated tablet - 400 milligram(s) - other antineoplastic agents - protein-tyrosine kinase inhibitor - imatinib is indicated for the treatment of: paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) an
imatinib 100 mg film-coated tablets
mcdermott laboratories ltd., t/a gerard laboratories - imatinib - film-coated tablet - 100 milligram(s) - imatinib
imatinib 400 mg film-coated tablets
mcdermott laboratories ltd., t/a gerard laboratories - imatinib - film-coated tablet - 400 milligram(s) - imatinib
imatinib krka d.d 100 mg film-coated tablets
krka, d.d., novo mesto - imatinib mesilate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib
imatinib krka d.d. 400 mg film-coated tablets
krka, d.d., novo mesto - imatinib mesilate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib
imatinib fresenius kabi 100 mg film-coat. tabl.
fresenius kabi deutschland gmbh - imatinib mesilate 119,5 mg - eq. imatinib 100 mg - film-coated tablet - 100 mg - imatinib mesilate 119.5 mg - imatinib